Inogen

INGN

Market cap $217M

Inogen (INGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Appointment of Naga Rameswamy as Chief Technology Officer.

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Inogen (INGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Teleflex, Integer Holdings and Inogen are defying tariff and supply chain headwinds with genAI-driven momentum within the Medical Instruments industry.

The mean of analysts' price targets for Inogen (INGN) points to a 49.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Inogen, Inc. (NASDAQ:INGN ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Kevin R. M. Smith - President, CEO & Director Lorna Williams - Corporate Participant Michael J.

INGN stock rises as Q2 loss narrows and revenue climbs 4% year over year, driven by strong B2B demand despite DTC and rental declines.

Inogen (INGN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.24 per share a year ago.

GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Second Quarter 2025 Financial Results; Delivered strong top-line results; raising full year 2025 revenue expectations.